Nanomedicine (NM)’s research focuses on the development of diagnostic and therapeutic approaches towards an early and unequivocal diagnosis and treatment of cancer, inflammatory and neurological diseases. NM works in close collaboration with the clinic to enable translational medical research and to approach the end-user, in an attempt to offer a better prognosis and personalized treatment. To this aim, NM covers from fundamental research on the identification and validation of diseases’ biomarkers and cellular interactions, to a more applied cross-disciplinary research focused on the development of technologies and nanostructures (inorganic, organic, hybrid) for precision disease diagnosis, therapy and theranostics, ranging from low to high technology readiness levels (TRLs).

NM field of action comprises in vitro (2D, 3D, OoC), ex vivo and in vivo experimentation and evolves in the frontier between Chemistry, Materials Science, Biophysics, Engineering and Biology, always within an international framework.

Nanomedicine evolves in the frontier between different disciplines of knowledge, such as chemistry, materials science, physics and biology, always within an international framework.

Research lines:

  • Theranostic probes
  • Animal‐free validation platforms



Alternative PROteins from MIcrobial fermentation of non-conventional SEA sources for Next-Generation food, feed and non-food bio-based applications


Brain-on-a-chip as a preclinical model tool for the screening of theranostic nanoformulations for neurodegenerative diseases